Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Authors
Keywords
-
Journal
CLINICAL MICROBIOLOGY REVIEWS
Volume 32, Issue 4, Pages -
Publisher
American Society for Microbiology
Online
2019-08-27
DOI
10.1128/cmr.00031-19
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interference With Quorum-Sensing Signal Biosynthesis as a Promising Therapeutic Strategy Against Multidrug-Resistant Pathogens
- (2019) Osmel Fleitas Martínez et al. Frontiers in Cellular and Infection Microbiology
- Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model
- (2019) Joan Gómez-Junyent et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology
- (2019) Ester del Barrio-Tofiño et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa
- (2018) Gloria Andolina et al. ACS Chemical Biology
- MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model
- (2018) Hoan N. Le et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
- (2018) Veronica Rico Caballero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects
- (2018) Keith A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis
- (2018) Nicholas S. Britt et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid
- (2018) Víctor M. Chávez-Jacobo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Avibactam Pharmacokinetic/Pharmacodynamic Targets
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models
- (2018) Francesca Forti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses
- (2018) Achim Wach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination With Imipenem and Cilastatin in Healthy Participants
- (2018) Elizabeth G. Rhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Murepavadin, a novel antipseudomonal antibiotic: Pharmacokinetics, tolerability and safety in subjects with mild, moderate, and severe renal function impairment
- (2018) Glenn E. Dale et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model
- (2018) Cornelia B. Landersdorfer et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model
- (2018) M. Montero et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program
- (2018) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa
- (2018) Yu-Wei Lin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae
- (2018) Safa S. Almarzoky Abuhussain et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin causes profound morphological alteration but minimal cytoplasmic membrane perforation in populations of Escherichia coli and Pseudomonas aeruginosa
- (2018) Noëlle H. O’Driscoll et al. ARCHIVES OF MICROBIOLOGY
- Piperacillin and ceftazidime produce the strongest synergistic phage–antibiotic effect in Pseudomonas aeruginosa
- (2018) Jumpei Uchiyama et al. ARCHIVES OF VIROLOGY
- Global emergence of the widespread Pseudomonas aeruginosa ST235 clone
- (2018) P. Treepong et al. CLINICAL MICROBIOLOGY AND INFECTION
- Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016
- (2018) Helio S. Sader et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Nebulization effects on structural stability of bacteriophage PEV 44
- (2018) Ariel Astudillo et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Phages & antibiotic resistance: are the most abundant entities on earth ready for a comeback?
- (2018) Colin Hill et al. Future Microbiology
- Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients
- (2018) Morgan Hakki et al. INFECTION
- Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections
- (2018) Laura Escolà-Vergé et al. INFECTION
- Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa : clinical and microbiological outcomes
- (2018) B. Dietl et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model
- (2018) Islam M. Ghazi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis
- (2018) Konstantinos Z. Vardakas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program
- (2018) A. Stewart et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm
- (2018) Raúl Recio et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013–2015)
- (2018) M.A. Pfaller et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Unexpected mechanisms of resistance in Dutch Pseudomonas aeruginosa isolates collected during 14 years of surveillance
- (2018) P.D. Croughs et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Intraclonal variations of resistance and phenotype in Pseudomonas aeruginosa epidemic high-risk clone ST308: A key to success within a hospital?
- (2018) F. Abdouchakour et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection
- (2018) Alan R Noel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
- (2018) Gregory G Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15
- (2018) Krystyna M Kazmierczak et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa
- (2018) R. Jain et al. Journal of Cystic Fibrosis
- Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis
- (2018) Konstantinos Z. Vardakas et al. JOURNAL OF INFECTION
- Pseudomonas aeruginosa PcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates
- (2018) D E Tabor et al. JOURNAL OF INFECTIOUS DISEASES
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- P. aeruginosa blood stream infection isolates: A “full house” of virulence genes in isolates associated with rapid patient death and patient survival
- (2018) K.L. McCarthy et al. MICROBIAL PATHOGENESIS
- Polymyxins for CNS infections: Pharmacology and neurotoxicity
- (2018) Tony Velkov et al. PHARMACOLOGY & THERAPEUTICS
- Challenges and Promises for Planning Future Clinical Research Into Bacteriophage Therapy Against Pseudomonas aeruginosa in Cystic Fibrosis. An Argumentative Review
- (2018) Martina Rossitto et al. Frontiers in Microbiology
- The Versatile Mutational Resistome of Pseudomonas aeruginosa
- (2018) Carla López-Causapé et al. Frontiers in Microbiology
- Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa
- (2018) Marc Xipell et al. Journal of Global Antimicrobial Resistance
- EVALUATION OF CEFTAZIDIME-AVIBACTAM FOR SERIOUS INFECTIONS DUE TO MULTIDRUG AND EXTENSIVE DRUG RESISTANT PSEUDOMONAS AERUGINOSA
- (2018) Olga Rodríguez-Núñez et al. Journal of Global Antimicrobial Resistance
- The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
- (2018) Lori L. Burrows ACS Infectious Diseases
- Engineering therapeutic antibodies to combat infectious diseases
- (2018) Ellen K Wagner et al. Current Opinion in Chemical Engineering
- Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients
- (2018) Vanessa E. Rees et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutation-Driven Evolution of Pseudomonas aeruginosa in the Presence of either Ceftazidime or Ceftazidime-Avibactam
- (2018) Fernando Sanz-García et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against Pseudomonas aeruginosa: PRIMERS IV
- (2018) Scott R Evans et al. CLINICAL INFECTIOUS DISEASES
- Phase 1 study of MEDI3902, an investigational anti–Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults
- (2018) S.O. Ali et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development
- (2018) Sherwin K. B. Sy et al. CLINICAL PHARMACOKINETICS
- Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
- (2018) Jianguo Li et al. CTS-Clinical and Translational Science
- Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
- (2018) Manuel Díaz-Cañestro et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia
- (2018) Thana Khawcharoenporn et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Deciphering β-lactamase-independent β-lactam resistance evolution trajectories in Pseudomonas aeruginosa
- (2018) Gabriel Cabot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages
- (2018) Tristan Ferry et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Intraventricular CNS treatment with Colistin-Tigecycline combination: A case series
- (2018) Vasiliki Tsolaki et al. JOURNAL OF CRITICAL CARE
- Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria
- (2018) Athina Pyrpasopoulou et al. JOURNAL OF INFECTION
- Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa
- (2018) Anneke van der Zee et al. Frontiers in Microbiology
- Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
- (2018) Mariadelfina Molinaro et al. Infection and Drug Resistance
- Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
- (2018) Tze-Peng Lim et al. Infection and Drug Resistance
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline?
- (2018) Despoina Koulenti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
- (2018) Shun-Chung Hsueh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
- (2018) Jason C Gallagher et al. Open Forum Infectious Diseases
- Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art
- (2017) Alberto Enrico Maraolo et al. Expert Review of Anti-Infective Therapy
- Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
- (2017) Aurélien Dinh et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Correlation between phenotypic antibiotic susceptibility and the resistome in Pseudomonas aeruginosa
- (2017) Magali Jaillard et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Unravelling the genome of a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 reveals an integrative conjugative element housing a blaGES-6 carbapenemase
- (2017) João Botelho et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16
- (2017) David M Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections
- (2017) Gregory G. Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases
- (2017) Helio S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The complete nucleotide sequence of an IncP-2 megaplasmid unveils a mosaic architecture comprising a putative novel blaVIM-2-harbouring transposon in Pseudomonas aeruginosa
- (2017) João Botelho et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa
- (2017) Marguerite L Monogue et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers
- (2017) Tommaso Giani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L
- (2017) Senthil Natesan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16
- (2017) Andrew Walkty et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15)
- (2017) Michael A. Pfaller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
- (2017) David M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluation of intraventricular colistin utilization: A case series
- (2017) Brian Gilbert et al. JOURNAL OF CRITICAL CARE
- Long-term mortality following Pseudomonas aeruginosa bloodstream infection
- (2017) K.L. McCarthy et al. JOURNAL OF HOSPITAL INFECTION
- Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections
- (2017) Carlos Juan et al. JOURNAL OF INFECTIOUS DISEASES
- Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study
- (2017) Silvia Gómez-Zorrilla et al. Microbial Drug Resistance
- Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
- (2017) Seth W. Dickey et al. NATURE REVIEWS DRUG DISCOVERY
- Differential Effect of Newly Isolated Phages Belonging to PB1-Like, phiKZ-Like and LUZ24-Like Viruses against Multi-Drug Resistant Pseudomonas aeruginosa under Varying Growth Conditions
- (2017) Simone Latz et al. Viruses-Basel
- Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps
- (2017) Jorge Olivares Pacheco et al. mBio
- Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone
- (2017) Carla López-Causapé et al. Scientific Reports
- The Power of Asymmetry: Architecture and Assembly of the Gram-Negative Outer Membrane Lipid Bilayer
- (2016) Jeremy C. Henderson et al. Annual Review of Microbiology
- Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
- (2016) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates
- (2016) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients
- (2016) Leonie Greipel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Deciphering the resistome of the widespreadP. aeruginosaST175 international high-risk clone through whole genome sequencing
- (2016) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014
- (2016) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
- (2016) Tsukasa Ito-Horiyama et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics
- (2016) Yanfang Feng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B
- (2016) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
- (2016) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms
- (2016) Gabriel Torrens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition
- (2016) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interaction of Avibactam with Class B Metallo-β-Lactamases
- (2016) Martine I. Abboud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
- (2016) Alexandre P. Zavascki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
- (2016) Juan José Castón et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
- (2016) Fekade Bruck Sime et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling
- (2016) Rajbharan Yadav et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro and in vivo Pharmacodynamics of Colistin and Aztreonam Alone and in Combination against Multidrug-Resistant Pseudomonas aeruginosa
- (2016) Yuka Yamagishi et al. CHEMOTHERAPY
- Dosing guidance for intravenous colistin in critically-ill patients
- (2016) Roger L Nation et al. CLINICAL INFECTIOUS DISEASES
- The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study
- (2016) Yael Dishon Benattar et al. CLINICAL INFECTIOUS DISEASES
- The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.
- (2016) Bruno François et al. CLINICAL INFECTIOUS DISEASES
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Phenotype and toxicity of the recently discovered exlA -positive Pseudomonas aeruginosa strains collected worldwide
- (2016) Emeline Reboud et al. ENVIRONMENTAL MICROBIOLOGY
- New β-Lactamase Inhibitors in the Clinic
- (2016) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate
- (2016) Juan P. Horcajada et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies
- (2016) Silvia Gómez-Zorrilla et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
- (2016) O. Asuphon et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
- (2016) Oren Zusman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study
- (2016) Alexandre Brasseur et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model
- (2016) Ami F. Mohamed et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- A cohort study of bacteremic pneumonia
- (2016) Cristina Vazquez Guillamet et al. MEDICINE
- Quorum sensing signal–response systems in Gram-negative bacteria
- (2016) Kai Papenfort et al. NATURE REVIEWS MICROBIOLOGY
- The Rrp6 C-terminal domain binds RNA and activates the nuclear RNA exosome
- (2016) Elizabeth V. Wasmuth et al. NUCLEIC ACIDS RESEARCH
- The HigB/HigA toxin/antitoxin system ofPseudomonas aeruginosainfluences the virulence factors pyochelin, pyocyanin, and biofilm formation
- (2016) Thammajun L. Wood et al. MicrobiologyOpen
- Utilization of Colistin for Treatment of Multidrug-ResistantPseudomonas aeruginosa
- (2016) Deana M Sabuda et al. Canadian Journal of Infectious Diseases & Medical Microbiology
- Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods
- (2015) Brian C. Nelson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective Observational Study of Prior Rectal Colonization Status as a Predictor for Subsequent Development of Pseudomonas aeruginosa Clinical Infections
- (2015) Silvia Gómez-Zorrilla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
- (2015) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice
- (2015) M. J. Melchers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1
- (2015) G. L. Drusano et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration
- (2015) Wesley D. Oliver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
- (2015) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular analysis of the integrons of metallo-β-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan
- (2015) Yoko Mano et al. BMC MICROBIOLOGY
- Targeting virulence not viability in the search for future antibacterials
- (2015) Begoña Heras et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Potent and Selective Modulation of the RhlR Quorum Sensing Receptor by Using Non-native Ligands: An Emerging Target for Virulence Control inPseudomonas aeruginosa
- (2015) Nora R. Eibergen et al. CHEMBIOCHEM
- Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?
- (2015) Roger L. Nation et al. CLINICAL INFECTIOUS DISEASES
- The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
- (2015) Xian-Zhi Li et al. CLINICAL MICROBIOLOGY REVIEWS
- The increasing threat of Pseudomonas aeruginosa high-risk clones
- (2015) Antonio Oliver et al. DRUG RESISTANCE UPDATES
- New promising β-lactamase inhibitors for clinical use
- (2015) I. Olsen EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Inhaled colistimethate sodium in ventilator-associated tracheobronchitis due to multidrug-resistant Gram-negative bacteria
- (2015) Luis Patricio Maskin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study
- (2015) Marta Tato et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
- (2015) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology
- (2015) Anaïs Potron et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Colistin and doripenem combinations againstPseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance
- (2015) Neang S. Ly et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Osteoarticular infection caused by MDRPseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams
- (2015) Alba Ribera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vivoevolution of resistance ofPseudomonas aeruginosastrains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure
- (2015) Mar Solé et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- High-Resolution Analysis by Whole-Genome Sequencing of an International Lineage (Sequence Type 111) of Pseudomonas aeruginosa Associated with Metallo-Carbapenemases in the United Kingdom
- (2015) Jane F. Turton et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
- (2015) Alan J. Xiao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
- (2015) Roger L Nation et al. LANCET INFECTIOUS DISEASES
- Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung
- (2015) Julio Diaz Caballero et al. mBio
- Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC
- (2014) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sequence Types 235, 111, and 132 Predominate among Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates in Croatia
- (2014) Marija Guzvinec et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic Pressure Is a Major Risk Factor for Rectal Colonization by Multidrug-Resistant Pseudomonas aeruginosa in Critically Ill Patients
- (2014) Silvia Gómez-Zorrilla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Novel Anti-PcrV Antibody Providing Enhanced Protection against Pseudomonas aeruginosa in Multiple Animal Infection Models
- (2014) Paul Warrener et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin-Induced Nephrotoxicity in Mice Involves the Mitochondrial, Death Receptor, and Endoplasmic Reticulum Pathways
- (2014) Chongshan Dai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2014) Tiffany R. Keepers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
- (2014) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
- (2014) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Resistome of Pseudomonas aeruginosa in Relationship to Phenotypic Susceptibility
- (2014) Veronica N. Kos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
- (2014) Ken Coleman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
- (2014) R. L. Nation et al. CLINICAL INFECTIOUS DISEASES
- Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections
- (2014) C. Pena et al. CLINICAL INFECTIOUS DISEASES
- Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species
- (2014) S.M. Diene et al. CLINICAL MICROBIOLOGY AND INFECTION
- Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa
- (2014) A.A. Witney et al. CLINICAL MICROBIOLOGY AND INFECTION
- Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China
- (2014) Y. Chen et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin
- (2014) A. Safarika et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Intraventricular or intrathecal colistin for the treatment of central nervous system infections caused by multidrug-resistant Gram-negative bacteria
- (2014) Roberto Imberti et al. Expert Review of Anti-Infective Therapy
- Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update
- (2014) Jean-Louis Vincent Future Microbiology
- Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections
- (2014) G. Samonis et al. INFECTION
- Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)
- (2014) Helio S. Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa
- (2014) Alicia Fajardo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
- (2014) R. K. Flamm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
- (2014) M. Castanheira et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Treatment of Multidrug-ResistantPseudomonas aeruginosaUsing Extended-Infusion Antimicrobial Regimens
- (2014) Emily L. Heil et al. PHARMACOTHERAPY
- The Impact of Antimicrobial Resistance and Aging in VAP Outcomes: Experience from a Large Tertiary Care Center
- (2014) Marios Arvanitis et al. PLoS One
- Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria
- (2014) Abiola O. Olaitan et al. Frontiers in Microbiology
- Pseudomonas aeruginosaVentilator-associated Pneumonia. Predictive Factors of Treatment Failure
- (2013) Benjamin Planquette et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones
- (2013) Xavier Mulet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems
- (2013) Oren Zusman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
- (2013) David J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa
- (2013) Sophie Guénard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymyxin Resistance ofPseudomonas aeruginosa phoQMutants Is Dependent on Additional Two-Component Regulatory Systems
- (2013) Alina D. Gutu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combined Intravenous and Intraventricular Administration of Colistin Methanesulfonate in Critically Ill Patients with Central Nervous System Infection
- (2013) Mairi Ziaka et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells
- (2013) Mohammad A. K. Azad et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study
- (2013) Luisa Sorlí et al. BMC INFECTIOUS DISEASES
- Antibiotic Resistance inPseudomonas Aeruginosais Associated with Decreased Fitness
- (2013) Zhenzhen Sun et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
- (2013) H. W. Boucher et al. CLINICAL INFECTIOUS DISEASES
- Pseudomonas aeruginosa Virulence and Antimicrobial Resistance
- (2013) Alan R. Hauser CRITICAL CARE MEDICINE
- Assessment of Severity of ICU-Acquired Pneumonia and Association With Etiology
- (2013) Marta Di Pasquale et al. CRITICAL CARE MEDICINE
- Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality
- (2013) C. Peña et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics
- (2013) Tony Velkov et al. Future Microbiology
- Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
- (2013) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Selective advantages of two major clones of carbapenem-resistant Pseudomonas aeruginosa isolates (CC235 and CC641) from Korea: antimicrobial resistance, virulence and biofilm-forming activity
- (2013) Ji-Young Lee et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing
- (2013) D. Skurnik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
- (2012) Qin Lu et al. ANESTHESIOLOGY
- Quantitative Contributions of Target Alteration and Decreased Drug Accumulation to Pseudomonas aeruginosa Fluoroquinolone Resistance
- (2012) Sebastian Bruchmann et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pan-β-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities
- (2012) Bartolomé Moyá et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones
- (2012) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosapneumonia
- (2012) So-Youn Park et al. BMC INFECTIOUS DISEASES
- Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative Bacteremia
- (2012) Giulia Vicari et al. CLINICAL INFECTIOUS DISEASES
- Costs of Healthcare- and Community-Associated Infections With Antimicrobial-Resistant Versus Antimicrobial-Susceptible Organisms
- (2012) Matthew J. Neidell et al. CLINICAL INFECTIOUS DISEASES
- High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study
- (2012) L. Dalfino et al. CLINICAL INFECTIOUS DISEASES
- Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients
- (2012) C. Peña et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients
- (2012) Zoe E. Athanassa et al. INTENSIVE CARE MEDICINE
- Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin
- (2012) Anucha Apisarnthanarak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Challenges for accurate susceptibility testing, detection and interpretation of -lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study
- (2012) C. Juan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?
- (2012) Konstantinos Z. Vardakas et al. JOURNAL OF INFECTION
- Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study
- (2011) Gabriel Cabot et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula
- (2011) Phillip J. Bergen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa
- (2011) G. L. Drusano et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth
- (2011) Xavier Mulet et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model
- (2011) Phillip J. Bergen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
- (2011) S. M. Garonzik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections
- (2011) Carmen Peña et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa
- (2011) Reinout Naesens et al. BMC INFECTIOUS DISEASES
- Colistin pharmacokinetics: the fog is lifting
- (2011) W. Couet et al. CLINICAL MICROBIOLOGY AND INFECTION
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*
- (2011) Ali A. El-Solh et al. CRITICAL CARE MEDICINE
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates
- (2011) G. Samonis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Status report on carbapenemases: challenges and prospects
- (2011) Gopi Patel et al. Expert Review of Anti-Infective Therapy
- Efficacy and Safety of Colistin in the Treatment of Infections Caused by Multidrug-resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancy: A Matched Pair Analysis
- (2011) Nadira Durakovic et al. INTERNAL MEDICINE
- Adaptive resistance to cationic compounds in Pseudomonas aeruginosa
- (2011) Anna Skiada et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- The revival of fosfomycin
- (2011) Argyris S. Michalopoulos et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa
- (2011) K. Abdelraouf et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem
- (2011) E. Riera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Most Multidrug-Resistant Pseudomonas aeruginosa Isolates from Hospitals in Eastern France Belong to a Few Clonal Types
- (2011) Pascal Cholley et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Impact of Multidrug Resistance on Experimental Empyema by Pseudomonas aeruginosa
- (2011) Evangelos J. Giamarellos-Bourboulis et al. RESPIRATION
- Pseudomonas aeruginosa: all roads lead to resistance
- (2011) Elena B.M. Breidenstein et al. TRENDS IN MICROBIOLOGY
- Pseudomonas Aeruginosa: Resistance to the Max
- (2011) Keith Poole Frontiers in Microbiology
- High-Dose Continuous Infusion β-Lactam Antibiotics for the Treatment of Resistant Pseudomonas Aeruginosa Infections in Immunocompromised Patients
- (2010) Brad Moriyama et al. ANNALS OF PHARMACOTHERAPY
- Amikacin Monotherapy for Sepsis Caused by Panresistant Pseudomonas aeruginosa
- (2010) B. Layeux et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and β-Lactams inPseudomonas aeruginosa
- (2010) Cédric Muller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of a New Cephalosporin, CXA-101 (FR264205), against -Lactam-Resistant Pseudomonas aeruginosa Mutants Selected In Vitro and after Antipseudomonal Treatment of Intensive Care Unit Patients
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression
- (2010) A. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genetic Determinants Involved in the Susceptibility of Pseudomonas aeruginosa to -Lactam Antibiotics
- (2010) C. Alvarez-Ortega et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Serum and Cerebrospinal Fluid Levels of Colistin in Pediatric Patients
- (2010) C. Antachopoulos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Use of High‐Dose 4‐Hour Infusion of Doripenem, in Combination with Fosfomycin, for Treatment of Carbapenem‐ResistantPseudomonas aeruginosaPneumonia
- (2010) Anucha Apisarnthanarak et al. CLINICAL INFECTIOUS DISEASES
- Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
- (2010) Chien-Yu Cheng et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection
- (2010) Cristina Suárez et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- New insights into the antibacterial mechanism of action of squalamine
- (2010) K. Alhanout et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic
- (2010) L. S. Elias et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antibiotic resistance and its cost: is it possible to reverse resistance?
- (2010) Dan I. Andersson et al. NATURE REVIEWS MICROBIOLOGY
- Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa
- (2010) S. Han et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes
- (2010) Elizabeth B Hirsch et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Quorum Sensing Inhibition Selects for Virulence and Cooperation in Pseudomonas aeruginosa
- (2010) Thilo Köhler et al. PLoS Pathogens
- Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers
- (2009) H. Lazar et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 Pseudomonas aeruginosa Isolates Producing the Extended-Spectrum -Lactamases GES-1 and GES-5 in Spain
- (2009) E. Viedma et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Penetration of Colistin into Cerebrospinal Fluid
- (2009) S. L. Markantonis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria
- (2009) D. Plachouras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genomewide Identification of Genetic Determinants of Antimicrobial Drug Resistance in Pseudomonas aeruginosa
- (2009) A. Dotsch et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains
- (2009) Aleksander Deptuła et al. ARCHIVES OF MICROBIOLOGY
- Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
- (2009) P. D. Lister et al. CLINICAL MICROBIOLOGY REVIEWS
- Role of Pseudomonas aeruginosa type III effectors in disease
- (2009) Joanne Engel et al. CURRENT OPINION IN MICROBIOLOGY
- Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections
- (2009) M. Montero et al. INFECTION
- Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies
- (2009) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
- (2009) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa
- (2009) N. Aoki et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Structure−Activity Relationships of Polymyxin Antibiotics
- (2009) Tony Velkov et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of meningitis due to antibiotic-resistant Acinetobacter species
- (2009) Baek-Nam Kim et al. LANCET INFECTIOUS DISEASES
- β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein
- (2009) Bartolomé Moya et al. PLoS Pathogens
- The Impact of Antimicrobial‐Resistant, Health Care–Associated Infections on Mortality in the United States
- (2008) R. Monina Klevens et al. CLINICAL INFECTIOUS DISEASES
- Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
- (2008) N. Petrosillo et al. CLINICAL MICROBIOLOGY AND INFECTION
- An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial Activity
- (2008) M. Baer et al. INFECTION AND IMMUNITY
- Nosocomial bloodstream infections due to metallo- -lactamase-producing Pseudomonas aeruginosa
- (2008) A. P. Zavascki et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started